These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 16957418)

  • 1. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol).
    Maggi M; Crescioli C; Morelli A; Colli E; Adorini L
    J Endocrinol Invest; 2006; 29(7):665-74. PubMed ID: 16957418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol).
    Adorini L; Penna G; Amuchastegui S; Cossetti C; Aquilano F; Mariani R; Fibbi B; Morelli A; Uskokovic M; Colli E; Maggi M
    J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):689-93. PubMed ID: 17241782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia.
    Adorini L; Penna G; Fibbi B; Maggi M
    Ann N Y Acad Sci; 2010 Apr; 1193():146-52. PubMed ID: 20398021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation.
    Comeglio P; Chavalmane AK; Fibbi B; Filippi S; Marchetta M; Marini M; Morelli A; Penna G; Vignozzi L; Vannelli GB; Adorini L; Maggi M
    J Endocrinol Invest; 2010 Nov; 33(10):730-8. PubMed ID: 20386089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.
    Fibbi B; Penna G; Morelli A; Adorini L; Maggi M
    Int J Androl; 2010 Jun; 33(3):475-88. PubMed ID: 19508330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human bladder as a novel target for vitamin D receptor ligands.
    Crescioli C; Morelli A; Adorini L; Ferruzzi P; Luconi M; Vannelli GB; Marini M; Gelmini S; Fibbi B; Donati S; Villari D; Forti G; Colli E; Andersson KE; Maggi M
    J Clin Endocrinol Metab; 2005 Feb; 90(2):962-72. PubMed ID: 15572423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.
    Penna G; Fibbi B; Amuchastegui S; Corsiero E; Laverny G; Silvestrini E; Chavalmane A; Morelli A; Sarchielli E; Vannelli GB; Gacci M; Colli E; Maggi M; Adorini L
    Prostate; 2009 Apr; 69(5):480-93. PubMed ID: 19107880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder.
    Morelli A; Vignozzi L; Filippi S; Vannelli GB; Ambrosini S; Mancina R; Crescioli C; Donati S; Fibbi B; Colli E; Adorini L; Maggi M
    Prostate; 2007 Feb; 67(3):234-47. PubMed ID: 17163492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility.
    Tiwari A
    IDrugs; 2009 Jun; 12(6):381-93. PubMed ID: 19517319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia.
    Crescioli C; Ferruzzi P; Caporali A; Scaltriti M; Bettuzzi S; Mancina R; Gelmini S; Serio M; Villari D; Vannelli GB; Colli E; Adorini L; Maggi M
    Eur J Endocrinol; 2004 Apr; 150(4):591-603. PubMed ID: 15080791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog.
    Crescioli C; Ferruzzi P; Caporali A; Mancina R; Comerci A; Muratori M; Scaltriti M; Vannelli GB; Smiroldo S; Mariani R; Villari D; Bettuzzi S; Serio M; Adorini L; Maggi M
    Endocrinology; 2003 Jul; 144(7):3046-57. PubMed ID: 12810561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D receptor as a therapeutic target for benign prostatic hyperplasia.
    Manchanda PK; Kibler AJ; Zhang M; Ravi J; Bid HK
    Indian J Urol; 2012 Oct; 28(4):377-81. PubMed ID: 23450267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease.
    Laverny G; Penna G; Vetrano S; Correale C; Nebuloni M; Danese S; Adorini L
    Immunol Lett; 2010 Jun; 131(1):49-58. PubMed ID: 20350569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are vitamin D receptor activators useful for the treatment of thrombosis?
    Wu-Wong JR
    Curr Opin Investig Drugs; 2009 Sep; 10(9):919-27. PubMed ID: 19705334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel nonsecosteroidal VDR agonist (CH5036249) exhibits efficacy in a spontaneous benign prostatic hyperplasia beagle model.
    Taniguchi K; Katagiri K; Kashiwagi H; Harada S; Sugimoto Y; Shimizu Y; Arakawa H; Ito T; Yamazaki M; Watanabe T; Kato A; Hoshino E; Takahashi T; Esaki T; Suzuki M; Takeda S; Ichikawa F; Harada A; Sekiguchi N; Ishigai M; Kawata H; Yoneya T; Onuma E; Sudoh M; Aoki Y
    J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):204-7. PubMed ID: 20304062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation.
    Mariani M; Viganò P; Gentilini D; Camisa B; Caporizzo E; Di Lucia P; Monno A; Candiani M; Somigliana E; Panina-Bordignon P
    Hum Reprod; 2012 Jul; 27(7):2010-9. PubMed ID: 22588001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential role for the VDR agonist elocalcitol in metabolic control: Evidences in human skeletal muscle cells.
    Antinozzi C; Corinaldesi C; Giordano C; Pisano A; Cerbelli B; Migliaccio S; Di Luigi L; Stefanantoni K; Vannelli GB; Minisola S; Valesini G; Riccieri V; Lenzi A; Crescioli C
    J Steroid Biochem Mol Biol; 2017 Mar; 167():169-181. PubMed ID: 28042053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
    Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
    Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia.
    Crescioli C; Maggie M; Vannelli GB; Luconi M; Salerno R; Barni T; Gulisano M; Forti G; Serio M
    J Clin Endocrinol Metab; 2000 Jul; 85(7):2576-83. PubMed ID: 10902811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases.
    Adorini L
    Int Immunopharmacol; 2002 Jun; 2(7):1017-28. PubMed ID: 12188026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.